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Members of the fibroblast growth factor (FGF) family are believed to play critical roles during 
organogenesis and carcinogenesis via signaling between epithelial and stromal compartments. Two 
new studies in this issue of Cancer Cell underscore the importance of FGF signaling in mediating 
epithelial-stromal interactions during prostate carcinogenesis. These papers show that deregulated 
FGF signaling in mouse models of prostate cancer leads to cancer progression and promotes an 
epithelial-mesenchymal transition, suggesting that FGF receptor inhibitors may have therapeutic 
value for prostate cancer treatment.Long before it was fashionable to talk 
about the role of the tumor microen-
vironment in cancer development, the 
pioneering studies of Gerald Cunha 
and others identified the importance 
of epithelial-stromal interactions for 
formation and tumorigenesis of the 
prostate gland (Cunha et al., 1987). 
These investigators showed that the 
prostate is highly amenable for inves-
tigating the role of paracrine growth 
factor signaling between epithelial and 
stromal compartments, particularly 
since these signaling interactions can 
be recapitulated in vitro as well as in 
male nude mice hosts. In particular, 
Cunha and colleagues used tissue 
recombinations of isolated epithelium 
and mesenchyme (stroma) to define 
the tissue and cellular requirements for 
prostate formation, elucidate the roles 
of growth factor and androgen signal-
ing, and demonstrate the contribution 
of the stromal compartment to pros-
tate carcinogenesis (Cunha et al., 1987; 
Hayward et al., 2001). In particular, this 
work identified specific members of 
the FGF family as having central roles 
in mediating epithelial-mesenchymal 
interactions in the prostate.
FGFs are encoded by a highly 
conserved family of 22 mammalian 
genes, which can promote a range of biological effects, including mito-
genesis and cellular differentiation, 
as well as increased cellular motility 
and invasiveness in specific contexts 
(Kwabi-Addo et al., 2004; Ornitz and 
Itoh, 2001). FGF ligands signal through 
four cognate high-affinity tyrosine 
kinase receptors, designated FGFR-1 
to -4, leading to downstream activa-
tion of multiple signal transduction 
pathways, including the Erk, MAPK, 
and PI3K-Akt pathways. During pros-
tate organogenesis, FGF10 expres-
sion in the mesenchyme is essential 
for prostate induction, acting inde-
pendently of the androgen receptor 
(AR) signaling pathway (Thomson and 
Cunha, 1999). Conversely, epithelial 
expression of the FGFR2 IIIb isoform 
(FGFR2b), which specifically binds 
FGF10, as well as FGF7 and FGF22, is 
essential for normal prostate organo-
genesis in an AR-independent man-
ner (Lin et al., 2007).
Several previous studies have 
shown that multiple FGF ligands dis-
play elevated expression in prostate 
cancer and can potentially act as 
either paracrine or autocrine factors 
(Kwabi-Addo et al., 2004). In addi-
tion, prostate cancer progression 
has been associated with altered 
expression of specific FGF receptor Cancer Cell 12, isoforms; notably, epithelial FGFR2b 
is downregulated and has been pro-
posed to have tumor suppressor 
activity (Kwabi-Addo et al., 2004). 
However, the underlying mechanisms 
by which deregulated FGF signaling 
may promote prostate tumorigenesis 
are poorly understood, and the func-
tional consequences of pathway acti-
vation have not been investigated.
In this issue of Cancer Cell, two 
manuscripts provide new insights 
into the role of epithelial-stromal 
interactions in prostate tumorigen-
esis, through studies of the conse-
quences of FGF10 overexpression in 
the prostate stroma (Memarzadeh et 
al., 2007), or of FGFR1 in the prostate 
epithelium (Acevedo et al., 2007). In 
the first paper, Witte and colleagues 
have adapted a tissue recombination 
approach to investigate the molecular 
factors involved in prostate formation 
and cancer (Memarzadeh et al., 2007). 
Using lentiviral delivery to manipulate 
gene expression in the stromal com-
partment, they have shown that stro-
mal overexpression of FGF10 results 
in epithelial hyperproliferation that is 
correlated with upregulation of AR 
expression. Furthermore, recombina-
tion of stroma overexpressing FGF10 
with epithelium expressing activated December 2007 ©2007 Elsevier Inc. 495
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Stromal expression of FGF10 (or perhaps another FGF) leads to activation of FGFR1 in the epithelium, resulting in hyperplasia and PIN. Further 
stimulation of the FGFR signaling pathway, together with additional transforming events, leads to increased expression of androgen receptor (AR) 
and activation of Akt, as well as upregulation of Sox9 and an epithelial-mesenchymal transition (EMT).Akt (myristoylated AKT1) results in 
cooperative effects on tumorigen-
esis. These findings are consistent 
with the synergy between AR and Akt 
in the prostate epithelium (Xin et al., 
2006), as well as the cooperativity of 
FGF8 overexpression and Pten inac-
tivation in mouse prostate tumorigen-
esis (Zhong et al., 2006).
Taken at face value, these results 
support a model in which stromal 
FGF10 drives tumorigenesis by 
upregulating AR signaling in the epi-
thelium, which in turn cooperates with 
Akt (Figure 1). Such a model fits with 
a growing body of evidence demon-
strating the critical roles of AR and 
the PI3K-Akt pathway in human pros-
tate carcinogenesis. One caveat is 
that FGF10 is not expressed in human 
prostate cancer samples (Ropiquet et 
al., 2000), so the significance of these 
mouse studies for human cancer is 
presently uncertain. Nonetheless, it 
is conceivable that another member 
of the FGF family may be relevant in 
vivo, such as FGF7 or FGF22, which 
have similar receptor-binding speci-
ficities to FGF10.
In a complementary study, Spen-
cer and colleagues (Acevedo et al., 
2007) describe a complex set of 
phenotypic consequences following 
FGF pathway activation in the pros-
tate epithelium, although they do 
not address the potential role of AR 
signaling. These investigators have 
utilized a novel strategy for condi-496 Cancer Cell 12, December 2007 ©20tional and reversible activation of the 
FGFR1 cytoplasmic signaling domain 
mediated by a chemical inducer of 
receptor heterodimerization. Trans-
genic mice that conditionally acti-
vate FGFR1 in the prostate epithe-
lium using this methodology develop 
hyperplasia and prostatic intraepithe-
lial neoplasia (PIN), a prostate cancer 
precursor, by 12 weeks of age (Free-
man et al., 2003).
In their new study, Spencer and col-
leagues report that FGFR1-activated 
mice up to 1 year of age can develop 
a spectrum of prostate malignancies, 
including adenocarcinoma as well 
as a low frequency of metastases 
to lymph nodes and liver (Acevedo 
et al., 2007). Interestingly, histologi-
cal analyses showed that these mice 
developed a greater incidence of a 
transitional sarcomatoid carcinoma 
with increasing age, consistent with 
the appearance of an epithelial-
mesenchymal transition (EMT). The 
occurrence of EMT is supported by 
expression profiling studies that dem-
onstrate elevated expression of Sox9, 
a known downstream target of FGF 
signaling, in both prostate tumors and 
metastases. Since Sox9 is expressed 
in human prostate cancer, it will be 
important to determine whether the 
expression of this putative transcrip-
tional regulator of EMT is correlated 
with elevated FGF signaling in human 
cancer, and whether expression of 
either Sox9 or FGFR1 is relevant for 07 Elsevier Inc.prostate cancer metastases. Taken 
together, these findings may be con-
sistent with a direct causal role for 
FGF signaling in prostate cancer, as 
suggested by the authors. However, 
the long latency of tumorigenesis and 
the FGFR1 independence of the more 
advanced tumors imply the neces-
sity of other cooperating events for 
prostate tumorigenesis, which will be 
important to identify in future studies.
Given the apparent complementar-
ity of these two new papers, can we 
conclude that the effects of FGF10 
are mediated by FGFR1 in vivo? Here, 
the data are less clear. Witte and col-
leagues show that the transform-
ing effects of stromal FGF10 can be 
blocked by epithelial expression of a 
truncated FGFR1 receptor that acts 
as a dominant-negative, but only par-
tially by a dominant-negative FGFR2. 
This result suggests that FGF10 sig-
naling is indeed mediated by FGFR1, 
although the interpretation of such 
dominant-negative experiments can 
potentially be complicated by recep-
tor heterodimerization. Moreover, 
FGFR2 is unlikely to be a candidate 
receptor for stromal FGF10, since 
inducible overexpression of FGFR2 
in the prostate epithelium does not 
lead to a hyperplastic phenotype, 
indicating that FGFR1 and FGFR2 are 
not equivalent in their functional con-
sequences (Freeman et al., 2003). In 
contrast, however, previous studies 
have indicated that FGF10 activity 
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tor isoform in vivo and only signals 
weakly through the FGFR1b isoform 
(Ornitz and Itoh, 2001; Zhang et al., 
2006). One possible explanation is 
that high levels of FGF10 may be suf-
ficient to activate FGFR1 in vivo—fur-
ther analyses of FGF10 signaling in 
the prostate will undoubtedly shed 
additional light on this issue.
In summary, the two new manu-
scripts in this issue of Cancer Cell 
indicate that paracrine actions of FGF 
signaling between stromal and epi-
thelial compartments may be critical 
for prostate tumorigenesis, as has 
long been proposed in the literature. 
These provocative studies open new 
avenues for further research, particu-
larly to determine how FGFR pathway 
activation can drive EMT and promote 
metastasis. Notably, the interactions 
between FGFR signaling and the AR The development of technologies 
that facilitate genome-scale analyses 
of gene expression, DNA sequence 
variation, protein accumulation, pro-
tein interactions, DNA copy number, 
and more has had a transforming 
effect on biology and medicine. This 
is perhaps best seen in cancer, where 
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may exist for targeting FGF recep-
tors in conjunction with Akt or related 
pathway inhibitors.
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